Search
Vericel Corp
VCELAdd to Watchlist
38.790USD
-1.430-3.56%
Close 09-23 16:00（ET）
1.98BMarket Cap
90.48P/E TTM
About Vericel Corp Company
Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full-thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adult and pediatric patients with deep partial thickness and/or full-thickness thermal burns.
Vericel Corp Profile
Ticker SymbolVCEL
Company nameVericel Corp
IPO dateFeb 04, 1997
CEOColangelo (Dominick C)
Number of employees357
Security typeOrdinary Share
Fiscal year-endFeb 04
Address64 Sidney St
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02139
Phone17349305555
Websitehttps://vcel.com/
Ticker SymbolVCEL
IPO dateFeb 04, 1997
CEOColangelo (Dominick C)
Company Executives of Vericel Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Dominick C. Colangelo
Mr. Dominick C. Colangelo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
312.90K
+0.21%
Mr. Dominick C. Colangelo
Mr. Dominick C. Colangelo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
312.90K
+0.21%
Mr. Dominick C. Colangelo
Mr. Dominick C. Colangelo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
312.90K
+0.21%
Dr. Jonathan Mark Hopper
Dr. Jonathan Mark Hopper
Chief Medical Officer
Chief Medical Officer
75.73K
--
Dr. Jonathan Mark Hopper
Dr. Jonathan Mark Hopper
Chief Medical Officer
Chief Medical Officer
75.73K
--
Dr. Jonathan Mark Hopper
Dr. Jonathan Mark Hopper
Chief Medical Officer
Chief Medical Officer
75.73K
--
Mr. Alan L. Rubino
Mr. Alan L. Rubino
Independent Director
Independent Director
64.19K
+4.98%
Mr. Alan L. Rubino
Mr. Alan L. Rubino
Independent Director
Independent Director
64.19K
+4.98%
Mr. Alan L. Rubino
Mr. Alan L. Rubino
Independent Director
Independent Director
64.19K
+4.98%
Ms. Heidi M. Hagen
Ms. Heidi M. Hagen
Independent Director
Independent Director
35.05K
+9.13%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Dominick C. Colangelo
Mr. Dominick C. Colangelo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
312.90K
+0.21%
Mr. Dominick C. Colangelo
Mr. Dominick C. Colangelo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
312.90K
+0.21%
Mr. Dominick C. Colangelo
Mr. Dominick C. Colangelo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
312.90K
+0.21%
Dr. Jonathan Mark Hopper
Dr. Jonathan Mark Hopper
Chief Medical Officer
Chief Medical Officer
75.73K
--
Dr. Jonathan Mark Hopper
Dr. Jonathan Mark Hopper
Chief Medical Officer
Chief Medical Officer
75.73K
--
Dr. Jonathan Mark Hopper
Dr. Jonathan Mark Hopper
Chief Medical Officer
Chief Medical Officer
75.73K
--
FAQs
Who are the top five shareholders of Vericel Corp?
The top five shareholders of Vericel Corp are: Mr. Dominick C. Colangelo
How many institutions hold shares of Vericel Corp (VCEL)?
As of 2026Q1, 583 institutions hold shares of Vericel Corp, with a combined market value of approximately 60.86M, accounting for 119.17% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 2568794.00.
What is the biggest source of revenue for Vericel Corp?
In 2026Q1, the MACI business generated the highest revenue for Vericel Corp, amounting to 65.51M and accounting for 84.57% of total revenue.